Loading...
XNAS
AFMD
Market cap14mUSD
May 02, Last price  
0.96USD
1D
-12.73%
1Q
-4.95%
Jan 2017
-94.67%
IPO
-98.50%
Name

Affimed NV

Chart & Performance

D1W1MN
P/E
—
P/S
1.53
EPS
—
Div Yield, %
—
Shrs. gr., 5y
19.81%
Rev. gr., 5y
-19.00%
Revenues
8m
-79.99%
1,173,0005,087,0003,382,0007,562,0006,314,0002,010,00023,735,00021,391,00028,360,00040,366,00041,353,0008,275,000
Net income
-106m
L+23.18%
-14,314,000-26,099,000-259,000-20,239,000-32,216,000-30,223,000-19,477,000-32,365,000-41,366,000-57,523,000-86,004,000-105,938,000
CFO
-110m
L+5.13%
-8,645,000-5,678,000-10,547,000-18,535,000-32,127,000-25,549,00049,438,000-29,056,000-19,400,000-86,591,000-104,892,000-110,269,000

Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
URL
https://www.affimed.com/
IPO date
Sep 12, 2014
Employees
219
Domiciled in
DE
Incorporated in
NL

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
8,275
-79.99%
41,353
2.45%
Cost of revenue
119,633
130,889
Unusual Expense (Income)
NOPBT
(111,358)
(89,536)
NOPBT Margin
Operating Taxes
3
2
Tax Rate
NOPAT
(111,361)
(89,538)
Net income
(105,938)
23.18%
(86,004)
49.51%
Dividends
Dividend yield
Proceeds from repurchase of equity
235
95,907
BB yield
Debt
Debt current
6,372
6,326
Long-term debt
20,178
12,435
Deferred revenue
464
1,083
Other long-term liabilities
24,637
Net debt
(46,348)
(171,525)
Cash flow
Cash from operating activities
(110,269)
(104,892)
CAPEX
(3,729)
(696)
Cash from investing activities
(36,059)
5,605
Cash from financing activities
(6,220)
88,557
FCF
(119,921)
(89,136)
Balance
Cash
72,898
190,286
Long term investments
Excess cash
72,484
188,218
Stockholders' equity
57,807
152,915
Invested Capital
19,815
43,909
ROIC
ROCE
EV
Common stock shares outstanding
14,940
14,236
Price
Market cap
EV
EBITDA
(109,609)
(86,637)
EV/EBITDA
Interest
1,806
1,630
Interest/NOPBT